CAS 911417-87-3

2-[3-[4-(1H-Indazol-5-ylamino)-2-quinazolinyl]phenoxy]-N-(1-methylethyl)acetamide

Description:

2-[3-[4-(1H-Indazol-5-ylamino)-2-quinazolinyl]phenoxy]-N-(1-methylethyl)acetamide is a synthetic organic compound characterized by its complex structure, which includes multiple aromatic rings and functional groups. This compound features an indazole moiety, a quinazoline derivative, and a phenoxy group, contributing to its potential biological activity. The presence of an acetamide functional group suggests it may exhibit properties typical of amides, such as hydrogen bonding capabilities. The compound's structure indicates it may interact with various biological targets, making it of interest in medicinal chemistry, particularly in the development of pharmaceuticals. Its CAS number, 911417-87-3, allows for easy identification in chemical databases. While specific physical properties such as solubility, melting point, and stability are not provided, compounds of this nature often exhibit moderate to high lipophilicity, which can influence their pharmacokinetic profiles. Overall, this compound represents a class of molecules that may have therapeutic potential, warranting further investigation into its biological effects and mechanisms of action.

Formula: C₂₆H₂₄N₆O₂

InChI: InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31)

InChI key: InChIKey=GKHIVNAUVKXIIY-UHFFFAOYSA-N

SMILES: N(C=1C2=C(N=C(N1)C3=CC(OCC(NC(C)C)=O)=CC=C3)C=CC=C2)C=4C=C5C(=CC4)NN=C5

Synonyms:

• 2-[3-[4-(1H-Indazol-5-ylamino)-2-quinazolinyl]phenoxy]-N-(1-methylethyl)acetamide
• 2-[3-[4-[(1H-Indazol-5-yl)amino]quinazolin-2-yl]phenoxy]-N-isopropylacetamide
• SLx 2119
• KD 025
• Acetamide, 2-[3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy]-N-(1-methylethyl)-
• CS-1555
• SLx2119
• Belumosudil (SLx-2119)
• 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide
• SLx-2119(KD-025)
• ROCK inhibitor 2
• ROCK inhibitor 2/ KD025.slx-2119
• SLX2119(KD025);SLX 2119(KD 025);SLX2119;KD025
• ROCK INHIBITOR;SLX-2119
• KD025 (SLx-2119)
• SLX 2119; SLX2119;KD-025
• 2-(3-(4-((2H-indazol-5-yl)amino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide
• SLx-2119 (ROCK inhibitor
• belumosudil
• Belumosudil(KD-025)
• KD025 (SLX-2119);SLX 2119;SLX2119

2-[3-[4-[(1H-Indazol-5-yl)amino]quinazolin-2-yl]phenoxy]-N-isopropylacetamide

CAS: 911417-87-3

Formula: C₂₆H₂₄N₆O₂

Purity: 99%

Color and Shape: Solid

Molecular weight: 452.5078

Ref: IN-DA003AGN

2-[3-[4-[(1H-Indazol-5-Yl)Amino]Quinazoline-2-Yl]Phenoxy]-N-Isopropylacetamide

CAS: 911417-87-3

2-[3-[4-[(1H-Indazol-5-Yl)Amino]Quinazoline-2-Yl]Phenoxy]-N-Isopropylacetamide

Purity: 99%

Molecular weight: 452.21g/mol

Ref: 54-OR1025711

Belumosudil-d7

CAS: 911417-87-3

Formula: C₂₆H₁₇D₇N₆O₂

Molecular weight: 459.56

Ref: 4Z-B-258002

Belumosudil

CAS: 911417-87-3

Belumosudil

Purity: ≥95%

Molecular weight: 452.51g/mol

Ref: 54-BUP13044

Belumosudil

CAS: 911417-87-3

Formula: C₂₆H₂₄N₆O₂

Molecular weight: 452.52

Ref: 4Z-B-258001

Belumosudil

CAS: 911417-87-3

Belumosudil (Rezurock) is an orally available, and specific ROCK2 inhibitor (IC50/Ki: 60/41 nM).

Formula: C₂₆H₂₄N₆O₂

Purity: 97.64% - 98.59%

Color and Shape: Solid

Molecular weight: 452.51

Ref: TM-T6867

KD 025

Controlled Product

CAS: 911417-87-3

Applications KD 025 is an inhibitor of Rho-associated protein kinase II (ROCK-II), a serine/threonine kinase that regulates the formation of actin stress fibers and focal adhesions, smooth muscle contraction, and gene expression (1, 2). KD025 has been shown to reduce infarct volume after transient middle cerebral artery occlusion (2).
References (1) Boerma, M. et a.: Biochem. Pharmacol. (2012) 83, 616-26 (2) Lee, J. et al.: Ann. Clin. Transl. Neurol. (2014) 1, 2-14

Formula: C₂₆H₂₄N₆O₂

Color and Shape: Neat

Molecular weight: 452.51

Ref: TR-K145600

SLX-2119

CAS: 911417-87-3

SLX-2119 is a small molecule that has been shown to have anti-fibrotic properties. It inhibits the growth of 3T3-L1 preadipocytes and reduces the expression of growth factor-β1, which is a key mediator in fibrosis. This drug also has potential as a biomarker for kidney fibrosis and malignant brain tumors. SLX-2119 is able to inhibit ROCK2, which may be an important pathogenic mechanism in bowel disease. The drug is metabolized by CYP450 enzymes and its metabolites are excreted through urine or bile. This compound has been shown to cause cell lysis in vitro, but this effect has not been observed in vivo.

Formula: C₂₆H₂₄N₆O₂

Purity: Min. 95%

Molecular weight: 452.52 g/mol

Ref: 3D-LLB41787